Entresto 49 mg+51 mg (Tablet)
Unit Price: ৳ 134.00 (2 x 14: ৳ 3,752.00)
Strip Price: ৳ 1,876.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Novartis bangladesh ltd |
| Also available as |
Indications
- Reduces risk of cardiovascular death
- Reduces hospitalization for heart failure
- Treats symptomatic heart failure
- Administered in conjunction with other therapies
- Used in place of ACE inhibitor or other ARB
Pharmacology
- Contains neprilysin inhibitor and angiotensin receptor blocker
- Inhibits neprilysin via LBQ657
- Blocks angiotensin II type-1 receptor via valsartan
- Increases levels of peptides degraded by neprilysin
- Simultaneously inhibits effects of angiotensin II
Dosage & Administration
- Adult Heart Failure: Starting dose is 49/51 mg orally twice daily
- Pediatric Heart Failure: Refer to pediatric dosing table
Interaction
- Should not be used with ACEi or aliskiren in diabetic patients
- Avoid use with ARB
- Potassium-sparing diuretics may increase serum potassium level
- NSAIDs may increase risk of renal impairment
- Lithium may increase risk of lithium toxicity
Contraindications
- Hypersensitivity to any component
- History of angioedema related to ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors
- Concomitant use of aliskiren in diabetic patients
Side Effects
- Angioedema
- Hypotension
- Impaired renal function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients <1 year
- No relevant pharmacokinetic differences in elderly patients
- No dose adjustment required in mild hepatic impairment
- Not recommended in severe hepatic impairment
- No dose adjustment required in mild to moderate renal impairment
- Recommended starting dose in severe renal impairment
Precautions & Warnings
- May cause angioedema
- Must not be used in patients with known history of angioedema
- May lower blood pressure and cause symptomatic hypotension
- Monitor serum creatinine
- Monitor serum potassium periodically
- Treat hyperkalemia appropriately
- Dosage reduction or interruption may be required
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No relevant pharmacokinetic differences in elderly patients
- Starting dose recommendation for severe renal impairment
- No starting dose adjustment for mild or moderate renal impairment
- Starting dose recommendation for moderate hepatic impairment
- No starting dose adjustment for mild hepatic impairment
- Not recommended in severe hepatic impairment
Overdose Effects
- Limited data available for human overdosage
- Hypotension is likely result of overdosage
- Symptomatic treatment should be provided
- Unlikely to be removed by hemodialysis
Storage Conditions
Keep in a dry place below 30°C, protect from moisture